UK markets closed

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.7050-0.1550 (-8.33%)
As of 02:44PM EDT. Market open.
Full screen
Loading interactive chart…
  • GlobeNewswire

    Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

    BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders. Dear Fellow Shareholders of Inhibikase Therapeutics: 2024 has been off to a productive start for Inhibikase. Our 2

  • GlobeNewswire

    Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

    Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company will meet wi

  • Simply Wall St.

    Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

    Inhibikase Therapeutics ( NASDAQ:IKT ) Full Year 2023 Results Key Financial Results Net loss: US$19.0m (loss widened by...